Age-related macular degeneration is one of the most common causes of blindness among the elderly population. The geriatric population is highly susceptible to different types of age-related diseases such as diabetes, renal insufficiency, arthritis, and macular degeneration. According to an article published in the BrightFocus Foundation in January 2019, the risk of getting affected by advanced age-related macular degeneration for people of age group of 50-59 is 2%, whereas it is around 30% among those who are over the age of 75 years. Hence, the high risk of age-related macular degeneration in geriatric population is anticipated to drive the growth of age-related macular degeneration therapeutics market during the forecast period.
Market Dynamics
Majority of pharmaceutical manufacturers operating in the North America & Europe age-related macular degeneration treatment market are engaged in adoption of inorganic growth strategies such as collaborations, partnerships, and acquisitions to strengthen their market share. These strategies have enabled market players to develop new drugs for treating AMD and enhance their existing portfolio of retinal products. For instance, in January 2020, Exonate, an early stage biotechnology company, collaborated with Janssen Pharmaceuticals, Inc., a pharmaceutical companies of Johnson & Johnson, to develop an eye drop treatment for retinal vascular diseases such as wet age-related macular degeneration treatment and diabetic macular oedema (DMO by using mRNA targeted therapies).
Key features of the study:
Detailed Segmentation:
North America & Europe Age-related Macular Degeneration Therapeutics Market, By Disease Type:
North America & Europe Age-related Macular Degeneration Therapeutics Market, By Drug Type:
North America & Europe Age-related Macular Degeneration Therapeutics Market, By Distribution Channel:
North America & Europe Age-related Macular Degeneration Therapeutics Market, By Region:
Company Profiles
“*” marked represents similar segmentation in other categories in the respective section.
Market Dynamics
Majority of pharmaceutical manufacturers operating in the North America & Europe age-related macular degeneration treatment market are engaged in adoption of inorganic growth strategies such as collaborations, partnerships, and acquisitions to strengthen their market share. These strategies have enabled market players to develop new drugs for treating AMD and enhance their existing portfolio of retinal products. For instance, in January 2020, Exonate, an early stage biotechnology company, collaborated with Janssen Pharmaceuticals, Inc., a pharmaceutical companies of Johnson & Johnson, to develop an eye drop treatment for retinal vascular diseases such as wet age-related macular degeneration treatment and diabetic macular oedema (DMO by using mRNA targeted therapies).
Key features of the study:
- This report provides in-depth analysis of the North America & Europe age-related macular degeneration therapeutics market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2020–2027), considering 2019 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the North America & Europe age-related macular degeneration therapeutics market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
- Key companies covered as a part of this study are Novartis AG, Bayer AG, Bausch Health Companies Inc., Regeneron Pharmaceuticals, Inc., F. Hoffmann-La Roche AG, Pfizer, Inc., and Valeant Pharmaceuticals International, Inc.
- Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future product launches, type up-gradation, market expansion, and marketing tactics
- The North America & Europe age-related macular degeneration therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the North America & Europe age-related macular degeneration therapeutics market.
Detailed Segmentation:
North America & Europe Age-related Macular Degeneration Therapeutics Market, By Disease Type:
- Dry AMD
- Wet AMD
North America & Europe Age-related Macular Degeneration Therapeutics Market, By Drug Type:
- Aflibercept (Eylea)
- Ranibizumab (Lucentis)
- Bevacizumab (Avastin)
- Pegaptanib (Macugen)
- Verteporfin (Visudyne)
- Brolucizumab (Beovu)
- Supplements
- Others
North America & Europe Age-related Macular Degeneration Therapeutics Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
North America & Europe Age-related Macular Degeneration Therapeutics Market, By Region:
- North America
- By Country
- U.S.
- Canada
- Latin America
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Country
- GCC
- Israel
- Rest of Middle East
- Africa
- By Country/Region
- South Africa
- Central Africa
- North Africa
Company Profiles
- Novartis AG*
- Company Overview
- Material Portfolio
- Financial Performance
- Key Highlights
- Market Strategies
- Bayer AG
- Bausch Health Companies Inc.
- Regeneron Pharmaceuticals, Inc.
- F. Hoffmann-La Roche AG
- Pfizer, Inc.
- Valeant Pharmaceuticals International, Inc.
“*” marked represents similar segmentation in other categories in the respective section.
Table of Contents
1. Research Objectives and Assumptions
2. Market Purview
3. Market Dynamics, Regulations, and Trends Analysis
4. North America & Europe Age-related Macular Degeneration Therapeutics Market - Impact of Coronavirus (Covid-19) Pandemic
2. North America & Europe Age-related Macular Degeneration Therapeutics Market, By Drug Type, 2016 - 2027, (US$ Mn)
3. North America & Europe Age-related Macular Degeneration Therapeutics Market, By Distribution Channel, 2016 - 2027, (US$ Mn)
4. North America & Europe Age-related Macular Degeneration Therapeutics Market, By Region, 2016 - 2027, (US$ Mn)
5. Competitive Landscape
6. Section
Companies Mentioned
A selection of companies mentioned in this report includes:
- Novartis AG
- Bayer AG
- Bausch Health Companies Inc.
- Regeneron Pharmaceuticals, Inc.
- F. Hoffmann-La Roche AG
- Pfizer, Inc.
- Valeant Pharmaceuticals International, Inc.
